Biotricity (NASDAQ: BTCY) Scores Another FDA Win with a 501-K Clearance for its Biotres Cardiac Monitoring Device

Biotricity (BTCY) Scores Another FDA Win with a 501-K Clearance for its Biotres Cardiac Monitoring Device

Good day everyone,

Biotricity, Inc. (NASDAQ: BTCY) shares are volatile this morning following the lead of the NASDAQ index, currently down by 395 points. BTCY dropped to $3.03 as of 10:13 am EST. We expect to see a rebound as this FDA Approval news rotates among the investment community.

In news this morning, BTCY reported it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Biotres Cardiac Monitoring Device, a three-lead device for ECG and arrhythmia monitoring that is intended for lower risk patients.

The company has said, “Biotres, is a holter for low-risk patients and is designed for comfort for long-term wear. Cardiac disease remains a chronic issue, requiring persistent intervention, monitoring and management and we believe Biotres may provide a critical tool for improving patient lives and reducing costs.”

The Biotres device works in tandem with the free Biotres app available at the App Store. The new FDA 510K clearance clears the way for sales of Biotres which the company estimates will begin starting April 1, 2022. Biotres could be a significant revenue generator for the company.

I want to clarify information regarding the S-3 filed by the company on Friday.

This prospectus relates to the public offering of up to 20,429,531 shares of our common stock, par value $0.001 per share (the “Common Stock”), by the selling stockholder which is comprised of shares of Common Stock issued to the selling stockholders upon the conversion of convertible promissory notes issued to certain selling stockholders pursuant to private placements between June 2020 and February 2021, shares of Common Stock and shares of Common Stock underlying Exchangeable Shares issued to certain investors in connection with the Company’s reverse take-over of iMedical Innovations Inc., shares of Common Stock issued to advisors and consultants of the Company between February 2016 and January 2022 as share-based compensation for services, and shares of Common Stock issued to certain shareholders in connection with private placements between February 2016 and June 2020.

The prospectus also states:

“We will not receive any proceeds from the sale of shares of common stock by the selling stockholders.”

Common Stock Outstanding before this offering 49,799,261 shares
Common Stock Outstanding after this offering 49,799,261 shares

Stay tuned for more information about BTCY.

The Traders News Group
original report below

Biotricity (BTCY) Game Changing Biotech with a Chart Signaling a Swing in Progress

Good day everyone and welcome to all of our new members,

I’ve been saying lately that Biotricity, Inc. (NASDAQ: BTCY) is becoming one of my favorite companies to report on. Like you, I watched the drastic fall in the NASDAQ index last week, wondering when the bloodletting would stop. At the end of the Friday session, I was going over my watch list and it was a sea of red with a notable exception.

BTCY closed in this past Friday’s session at $3.23/share, up on the day, not by much but as the NASDAQ gave up 385 points on Friday the tiny gain in BTCY shares intrigued me. I thought they must have had big news released, I checked and there was nothing that I hadn’t reported before. No earnings report (though I expect that in a couple of weeks), and no new product launches. That’s when I realized investors were simply “buying the dip” on the company shares.

The chart indicates a bounce is incoming with an RSI (14) of 38.66 and the MACD curling upward we could see a nice bounce here this week.

It was less than a month ago that BTCY shares hit a high of $5.30 and I think that they have found support in the current range. I also believe BTCY is on the right track for creating shareholder value.

In the back of my mind, I can hear Warren Buffet saying, “when everyone is selling, you should be buying.” I’ve said before that BTCY has impressive triple digit YoY revenue growth and a very modest share structure. I’ve talked about their impressive 66% gross margin and discussed their technology. I’ve talked about those aspects of BTCY as a reason to expect growth in the company’s value and they are valid reasons.

But my “big picture” reason for liking this company goes beyond their admirable performance. BTCY is reinventing the cardiac care industry and I think they will do the same thing to the diabetes care sector in the future.

Most companies developing biotech look at a sector and think “what kind of device can we sell that will fit with the physicians practice and make them more efficient?” Biotricity has a different approach which is more like welcoming physicians to the 21st century and saying, “it’s time to change the way you operate your practice because we have a more efficient innovative technology to do that.”

The BTCY eco-system promotes an initiative-taking approach to personal well-being and a higher level of connectivity with your physician. Their in-home monitoring devices, coupled with wireless transmission of data to the cloud, immediate alerts of critical events, and teleconferencing are integral components of a new standard of cardiac care.

The old process of visiting your cardiologist with a complaint, then going to get testing done, then returning to the doctor to discuss those results can be replaced with, or improved by, recent technology. The testing done by cardiologists today, give a snapshot of your condition at that moment whereas modern BTCY technology can make that a constant stream of data. Why can’t we replace those trips to the doctor’s office, and the waiting rooms with teleconferencing? BTCY thinks we can.

The benefits of constant cardiac monitoring and the ability to stream that data to your physician and even alerting them to a significant event, can’t be understated. Remote conferencing will be a huge benefit as well when a physician can increase the number of patients, they “see” in a day, and thanks to a product like Bio-Kit, all your vitals are readily available for that tele-conference.

Reinventing and disrupting the way doctors practice medicine with the BTCY model is a bold move. I believe physicians will embrace this kind of change more quickly than patients mainly because its cost effective to doctors and may increase their revenues. As I’ve said before, BTCY always looks toward how physicians can bill insurance companies for the technology they develop.

Can you imagine everything I said about transforming cardiac care above and applying that to the diabetes sector? Constant or frequent blood sugar monitoring with spikes in blood glucose levels alerted to your doctor and followed by a teleconference? Cardiac medicine and diabetes treatment are two of the largest revenue generators in modern medicine. The potential for BTCY to disrupt them is exciting.

The vision of the BTCY management and the development of their cardiac eco-system, are leading the way to a new paradigm in the patient physician relationship. So, do your own research and see if you think “buy the dip” applies here.

The Traders News Group


$BTCY, $ARDS, $JAGX, $BBIG #BTRTG, #Stocks, #wallstreetbets, #stockstobuy, #FDAapproval

Privacy Policy and Disclaimer

Your Consent

By using our site, you consent to our online privacy policy and disclaimer.

Do we disclose any information to outside parties?

We do not sell your information to anyone. Please see our cookie policy below.

What information do we collect?

We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.

When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.

What do we use your information for?

When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.

Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.

We send periodic emails

The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.

How do we protect your information?

We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and SMS messages to you.

Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.

Online Privacy Policy Policy

This online privacy policy applies to information collected through our website and social media platforms.

Contacting Us

If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.

Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The owners and operators of this website have been compensated twenty one thousand dollars cash via bank wire for our distributed opinions on btcy this week. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.

TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.

Biotricity SM Image